Recent Updates
Recently added Catalysts
SRPT Positive Sentiment

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Monday, October 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sarepta Therapeutics will present at the Wolfe Research and Guggenheim Securities healthcare conferences on November 9, 2026. Senior management will attend the New York and Boston events to discuss the company's progress. The Guggenheim presentation will also be available as a live webcast.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sarepta is recognized as a leader in precision genetic medicine.
  • Senior management will engage with investors at key conferences.
  • The participation highlights Sarepta's commitment to transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
8.4%
average across 9 past catalysts
Lead asset
SRP-9003
Phase 3 · Limb Girdle Muscular Dystrophy

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:8th Annual Wolfe Research Healthcare Conference in New York CityGuggenheim Securities 3rd Annual Healthcare Innovation Conference in BostonFireside chat: 3 p.m. ETThe presentation from the Guggenheim conference will be webcast live under the in

Frequently Asked Questions

When will Sarepta present at investor conferences?

Sarepta will present on November 9, 2026.

Where are the conferences taking place?

The conferences will be in New York City and Boston.

What is the focus of Sarepta Therapeutics?

Sarepta specializes in precision genetic medicine for rare diseases.

Who will represent Sarepta at the conferences?

Senior management will participate in the presentations.

ShareAdd on Google
Tags: SRPT Sarepta Therapeutics investor conferences healthcare innovation genetic medicine
Last updated: Oct 26, 2026

Biotech snapshot

Cash runway
$788M liquidity · $0M/mo burn
Low dilution risk
Lead asset
SRP-9003Phase 3
Limb Girdle Muscular Dystrophy →

Catalyst track record

+29%
best trade around SRPT's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for SRPT.

See every catalyst's timing & PoA →